BGI Genomics Empowers Brunei's National Cervical Cancer Prevention Program

January 16, 2025 03:51 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

SHENZHEN, China, Jan. 16, 2025 /PRNewswire/ -- On January 15, 2025, the Brunei Ministry of Health (MOH), in partnership with Borneo Genomics Innovation (BGIB), a joint venture of BGI Genomics in Brunei, launched the National Cervical Cancer Prevention and Control Program along with the 2025 National Guideline. The program aims to enhance early detection and eliminate cervical cancer across Brunei.

Group photo of the launch event
Group photo of the launch event

The launch event was attended by Dato Dr. Hj Mohd Isham, Minister of Health; Maswadi Hj Mohsin, Permanent Secretary of the Ministry of Health, Dr. Du Yutao, Chief Operating Officer of BGI Genomics; Jeremy Cao, Southeast Asia Regional General Manager of BGI Genomics; and other dignitaries.

At the event, Minister Dato Dr. Isham expressed his recognition and gratitude to the medical institutions and companies that participated in the program. He emphasized that the government is actively seeking partnerships with leading global health organizations to enhance the quality and accessibility of healthcare services for all citizens.

"BGI Genomics' HPV DNA testing can help Brunei efficiently carry out large-scale HPV screening. Looking ahead, we aspire to deepen our collaboration with Brunei to explore innovations in broader public health fields and advance the health and well-being of the Bruneian people," said Dr. Du.

The updated guideline highlights that HPV DNA-based testing as a primary tool for early detection offers a more accurate and reliable method compared to cytology. With royal family authorization and MOH leadership, this national project supports the WHO's global strategy of cervical cancer elimination by 2030 and demonstrates Brunei's dedication to local and global health goals.

This program incorporates a national HPV DNA screening initiative for all women aged 25 to 65. The HPV self-sampling kits are available at 32 clinics, four hospitals, and three gynecology wards in Brunei's four districts.

After the launch, Dato Dr. Isham met with Dr. Du and held in-depth discussions on future colorectal cancer screening program, multi-omics research, expert training and potential projects.

As another public health collaboration between BGI Genomics and the Brunei government, this initiative marks the transformation of BGI Genomics' first Huo-Yan Lab built in an ASEAN country. Through this collaboration, Brunei is taking a step towards a healthier national future.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.